Daiichi Sankyo Begins Trial for STING Agonist ADC DS-3610
November 10, 2025
The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. DS3610 is an investigational
